Organon & Co.
A global pharmaceutical company focused on women's health, with products from the contraceptive implant Nexplanon and the fertility drug Follistim AQ to biosimilars like Hadlima, sold across more than a hundred countries. The name comes from the Ancient Greek word for "an instrument for acquiring knowledge," the title of Aristotle's writings on logic. Founded in 1923 in the Netherlands to make insulin, the company was spun off from Merck in 2021, returning to its women's-health roots.
Granted 500.9K · Bought 34.0K
Granted 333.9K · Bought 11.4K
Granted 171.7K
Granted 169.0K
Granted 142.2K · Bought 5.5K
Bought 77.9K
Granted 110.0K · Bought 10.8K
Granted 66.9K · Bought 3.5K
Granted 103.7K
Granted 79.5K
Granted 58.4K
Granted 39.7K
Granted 67.1K
Granted 24.4K
Granted 21.7K · Sold 26.4K
Granted 16.3K
Granted 10.9K
Bought 3.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ali KevinChief Executive Officer, Director · 37 transactions | — | 282.7Kas of May 2025 | 500.9K | 34.0K | — |
| Walsh Matthew MChief Financial Officer · 43 transactions | — | 202.7K | 333.9K | 11.4K | — |
| Morrissey Joseph T. Jr.Interim CEO · 46 transactions | — | 123.1K | 171.7K | — | — |
| Stahler Rachel AChief Information Officer · 42 transactions | — | 110.3K | 169.0K | — | — |
| Falcione AaronChief Human Resources Officer · 47 transactions | — | 96.4K | 142.2K | 5.5K | — |
| Cox Carrie SmithExecutive Chair, Director · 2 transactions | — | 90.3K | — | 77.9K | — |
| Weaver KirkeGen. Counsel & Corp. Secy. · 38 transactions | — | 85.6K | 110.0K | 10.8K | — |
| Karp DanielExecutive VP, Corp. Dev. · 15 transactions | — | 71.7K | 66.9K | 3.5K | — |
| Nisita VittorioHead of Global Business Svcs · 46 transactions | — | 70.6K | 103.7K | — | — |
| Fiedler SusanneChief Commercial Officer · 26 transactions | — | 54.3Kas of Sep 2024 | 79.5K | — | — |
| DiMarco KathrynCorporate Controller · 28 transactions | — | 35.9Kas of Mar 2025 | 58.4K | — | — |
| Milligan SandraHead of Research & Development · 16 transactions | — | 30.8Kas of May 2023 | 39.7K | — | — |
| Arjona Ferreira Juan CamiloHead of R&D & CMO · 14 transactions | — | 30.0K | 67.1K | — | — |
| Drinane Juliana PapaInterim Head of Mfg & Supply · 7 transactions | — | 28.8K | 24.4K | — | — |
| Holzbaur LynetteSVP and Corporate Controller · 12 transactions | — | 26.4K | 21.7K | — | 26.4K |
| Ritter Geralyn SHead of Ext. Affairs and ESG · 16 transactions | — | 11.4Kas of May 2023 | 16.3K | — | — |
| Telman Deborah HEVP GC & Corporate Secretary · 4 transactions | — | 9.0Kas of May 2022 | 10.9K | — | — |
| Francisco Ma. FatimaDirector · 1 transaction | — | 3.0Kas of Jun 2023 | — | 3.0K | — |
| Merck & Co., Inc.10% owner · 1 transaction | — | 0as of Jun 2021 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +119.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.